financetom
Business
financetom
/
Business
/
FY22 revenue growth can be 10-15% in core businesses: Tube Investments
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FY22 revenue growth can be 10-15% in core businesses: Tube Investments
Feb 18, 2021 3:19 AM

Tube Investments registered good earnings in the third quarter with steady growth across the engineering and metal sheets segments. S Vellayan, MD of Tube Investments, talked about how are they seeing demand going forward and what are their Q4 and FY22 revenue expectations.

"Revenue growth will be in the range of like 10-15 percent on the core business. FY22 will our first year where we will basically have CG Power performance in it as well."

On CG Power, he said, "My sense is that the turnaround is definitely on track and if the economy picks up, the way we see industrial economy and hopefully the power sector picking up as well, then it can definitely give us a lot more impetus on the turnaround and perhaps can make it happen a bit more quickly than we thought it would happen before.”

Talking about growth in segments Vellayan said, "The overall bullishness in the economy is coming and stemming from public spending. If public spending plays out the way we see the government having articulated it, we think that both industrial and auto will really pick up the next year. Industrial is more dependent on public spending and auto is more consumer led, so we basically see that sector also picking up."

For full management commentary, watch the video.

(Edited by : Priyanka Rathi)

First Published:Feb 18, 2021 12:19 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AST SpaceMobile Secures Special Temporary Authority From FCC for Testing Service in US
AST SpaceMobile Secures Special Temporary Authority From FCC for Testing Service in US
Jan 31, 2025
05:04 AM EST, 01/31/2025 (MT Newswires) -- AST SpaceMobile ( ASTS ) said late Thursday it has received a special temporary authority from the Federal Communications Commission authorizing the company's testing service in the US. The authority enables the company's first five commercial BlueBird satellites with unmodified smartphones with partners AT&T ( T ) and Verizon (VZ) to support voice,...
India's top drugmaker Sun Pharma's Q3 profit beats estimates on strong local sales
India's top drugmaker Sun Pharma's Q3 profit beats estimates on strong local sales
Jan 31, 2025
HYDERABAD/BENGALURU Jan 31 (Reuters) - Sun Pharmaceutical, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong sales in the domestic market. The Mumbai-based firm's consolidated net profit rose 15% to 29.03 billion rupees ($335.3 million) in third quarter, beating analysts' average estimate of 28.81 billion rupees, according to data compiled by LSEG. ($1 =...
Exclusive-Scania tries to breathe life into troubled EV battery maker Northvolt
Exclusive-Scania tries to breathe life into troubled EV battery maker Northvolt
Jan 31, 2025
STOCKHOLM (Reuters) - Truckmaker Scania has stepped in to help Northvolt with the day-to-day running of its flagship plant in northern Sweden, a last-ditch effort to boost quality and output at the struggling electric vehicle battery maker as it scrambles to secure funds. Since November, Scania has sent members of staff to Northvolt's Ett plant located in Skelleftea, 200 kilometres...
Vertex Pharmaceuticals Sickle Cell Therapy to be Reimbursed by England's National Health Service
Vertex Pharmaceuticals Sickle Cell Therapy to be Reimbursed by England's National Health Service
Jan 31, 2025
04:55 AM EST, 01/31/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday it has made a reimbursement agreement with National Health Service England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy. The reimbursement agreement coincides with the UK National Institute for Health and Care Excellence recommending Casgevy's use by the NHS, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved